Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
LOCHOLEST LIGHT vs COLESTID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.
Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.
Adjunctive therapy to diet for reduction of elevated LDL cholesterol in primary hypercholesterolemia (Fredrickson Type IIa) in patients who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Off-label: adjunct in treatment of hyperthyroidism (binding of thyroxine), pseudomembranous colitis (binding of Clostridioides difficile toxins), and digoxin toxicity
Adjunctive therapy to diet for reduction of elevated serum total and LDL cholesterol in patients with primary hypercholesterolemia (type IIa) who do not respond adequately to diet,Pruritus associated with partial biliary obstruction,Digoxin toxicity (off-label),Hyperthyroidism (off-label),Pseudomembranous colitis (off-label)
LOCHOLEST LIGHT is not a recognized drug name. No data available.
5-10 g orally once or twice daily, maximum 30 g/day.
Terminal elimination half-life is approximately 19-24 hours; due to enterohepatic recirculation, effective half-life may be extended. Steady state is achieved within 4-6 weeks with continuous dosing.
Not applicable due to non-systemic action; local gastrointestinal half-life not clinically defined
Not metabolized; excreted unchanged in feces as the bile acid-resin complex.
Not absorbed systemically; not metabolized; excreted unchanged in feces.
Primarily biliary/fecal (approximately 75% as metabolites, <10% unchanged drug in feces); renal excretion accounts for about 20% of total elimination (mainly as inactive metabolites).
Primarily fecal (≥95%) as unchanged drug; minimal renal excretion (<5%)
Approximately 99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Not significantly absorbed; binding not applicable
Apparent volume of distribution is approximately 0.5-0.7 L/kg; extensive distribution into extravascular tissues, including the liver, which is the primary site of action.
Not applicable (non-absorbed; confined to gastrointestinal lumen)
Oral bioavailability is low (approximately 5-10%) due to extensive first-pass metabolism in the liver and gut wall; food increases absorption slightly (no dosage adjustment required).
Oral: <0.05% (negligible systemic absorption)
No data available.
No specific dosage adjustment required for renal impairment; use with caution in patients with renal dysfunction due to potential for hyperchloremic metabolic acidosis.
No data available.
No specific dosage adjustment required for hepatic impairment; use with caution in patients with pre-existing gastrointestinal disorders.
No data available.
Safety and efficacy not established; limited data suggest 5-10 g daily in divided doses for children aged 12-18 years.
No data available.
No specific dosage adjustment; monitor for constipation and gastrointestinal adverse effects; initiate at low end of dosing range.
No FDA boxed warning.
No FDA black box warning.
May cause hypertriglyceridemia; monitor triglycerides. Risk of bleeding due to vitamin K deficiency with long-term use. May reduce absorption of fat-soluble vitamins (A, D, E, K). Can cause fecal impaction; use with caution in constipation-prone patients. May bind other drugs; separate administration by at least 4 hours.
May cause fecal impaction, especially in patients with hemorrhoids or constipation.,May interfere with absorption of fat-soluble vitamins (A, D, E, K).,May reduce absorption of other drugs; take other medications at least 1 hour before or 4-6 hours after colestipol.,Use with caution in patients with bleeding tendencies or with impaired hepatic function.,Hypertriglyceridemia may occur.
Complete biliary obstruction (ineffective and may cause fecal impaction), hypersensitivity to any component, severe constipation or fecal impaction, hypolipidemic states (e.g., abetalipoproteinemia).
Complete biliary obstruction,Hypersensitivity to colestipol or any component of the formulation
Cholestyramine binds to bile acids and can interfere with absorption of fat-soluble vitamins (A, D, E, K). Patients should consume a diet rich in these vitamins or consider supplementation. High-fiber foods may aid in reducing constipation. Avoid excessive intake of high-fat foods as they may worsen hypertriglyceridemia.
Colestipol may bind to fat-soluble vitamins (A, D, E, K) and decrease their absorption. Take vitamin supplements at least 1 hour before or 4 hours after colestipol. High-fat meals may reduce binding efficacy; take with meals containing moderate fat.
First trimester: No evidence of teratogenicity in animal studies. Second and third trimesters: Potential risk of fetal harm due to possible maternal hypolipidemia, but no documented human fetal adverse effects. Overall, use only if clearly needed.
FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefore, fetal risk is considered minimal. Trimester-specific risks: First trimester: No known risk due to lack of absorption. Second and third trimesters: Potential for decreased absorption of fat-soluble vitamins and folate, which may affect fetal development. Vitamin K deficiency may increase neonatal bleeding risk.
Excretion in human milk unknown. Caution advised. M/P ratio not available.
Colestipol is not absorbed systemically, thus is not expected to be excreted into breast milk. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for potential gastrointestinal effects secondary to maternal use.
No specific dose adjustments recommended due to lack of pharmacokinetic studies in pregnancy.
No dose adjustment required due to lack of systemic absorption. However, ensure adequate nutritional status: monitor fat-soluble vitamin supplementation (A, D, E, K) and folate; increase interval between colestipol and prenatal vitamins/food to 1 hour before or 4 hours after.
Locholest Light (cholestyramine) is a bile acid sequestrant used for hyperlipidemia. Monitor for decreased absorption of fat-soluble vitamins (A, D, E, K) and consider supplementation. Administer other medications at least 1 hour before or 4-6 hours after cholestyramine to reduce binding. May increase triglyceride levels; avoid in patients with hypertriglyceridemia above 400 mg/d L. Can cause constipation; ensure adequate fluid and fiber intake.
Colestipol is a bile acid sequestrant; administer with meals to bind bile acids. Monitor for constipation and increase fluid/fiber intake. Reduce doses of other medications by at least 1 hour before or 4 hours after colestipol. May increase triglyceride levels; monitor lipids. Use with caution in patients with renal impairment.
Take cholestyramine exactly as prescribed, usually mixed with at least 4-6 ounces of fluid.,Do not take the powder dry; always mix with water, juice, or milk to avoid choking.,Take other medications at least 1 hour before or 4-6 hours after cholestyramine.,Drink plenty of fluids and eat high-fiber foods to prevent constipation.,Report unusual bleeding, bruising, or dark stools as signs of vitamin K deficiency.,This medication may increase triglyceride levels; monitor blood tests as directed.
Take exactly as prescribed, usually once or twice daily with food and a full glass of water.,Do not take other medications within 1 hour before or 4 hours after colestipol.,Drink plenty of fluids and eat high-fiber foods to prevent constipation.,Inform your doctor if you have a history of hemorrhoids or digestive problems.,Keep out of reach of children; store at room temperature.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about LOCHOLEST LIGHT vs COLESTID, answered by our medical review team.
LOCHOLEST LIGHT is a Bile Acid Sequestrant that works by Locholest Light is a bile acid sequestrant that binds bile acids in the intestine, forming an insoluble complex that is excreted in feces. This reduces enterohepatic circulation of bile acids, leading to increased conversion of cholesterol to bile acids in the liver and decreased serum LDL cholesterol.. COLESTID is a Bile Acid Sequestrant that works by Binds bile acids in the intestine, forming an insoluble complex that is excreted in the feces, thereby increasing fecal loss of bile acids and reducing enterohepatic circulation of bile salts. This leads to increased hepatic conversion of cholesterol to bile acids, reduction in hepatic cholesterol stores, and decreased plasma LDL cholesterol levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between LOCHOLEST LIGHT and COLESTID depend on the specific clinical indication. These are both Bile Acid Sequestrant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of LOCHOLEST LIGHT is: LOCHOLEST LIGHT is not a recognized drug name. No data available.. The standard adult dose of COLESTID is: 5-10 g orally once or twice daily, maximum 30 g/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between LOCHOLEST LIGHT and COLESTID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. LOCHOLEST LIGHT is classified as Category C. First trimester: No evidence of teratogenicity in animal studies. Second and third trimesters: Potential risk of fetal harm due to possible maternal hypolipidemia, but no documente. COLESTID is classified as Category C. FDA Pregnancy Category C. Animal studies have shown no evidence of teratogenicity at doses up to 10 times the human dose. However, colestipol is not absorbed systemically; therefor. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.